FDA Approves Cytokinetics' Myqorzo Label Update With Phase 3 MAPLE-HCM Data

By Public Technologies
  • Cytokinetics secured FDA clearance to add Phase 3 MAPLE-HCM results to the U.S. label for MYQORZO (aficamten).
  • The previously reported trial results showed greater improvements in exercise capacity, symptoms and cardiac biomarkers versus metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy.
  • MYQORZO is now the only cardiac myosin inhibitor with a U.S. label comparing its effectiveness with a beta blocker.
  • Overall adverse event rates were similar between treatment groups; hypertension occurred more frequently with MYQORZO.
  • The drug retains a boxed warning for heart failure risk, requiring echocardiogram monitoring and access through a restricted distribution program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160400PRIMZONEFULLFEED9878065) on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.